Immunotherapy - a potential new way forward in the treatment of sepsis.

Crit Care · 2013 · PMC4056021 · PMID 23425441

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

20 2 2013 17 1 118 118 13 6 2014 Copyright © 2013 BioMed Central Ltd Abstract A recent randomized controlled clinical trial of the immunostimulatory agent thymosin alpha-1 was conducted and showed a trend toward improved survival in patients receiving the drug ( P = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.